Trial Profile
Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2015
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- 11 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Apr 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 31 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.